MAPT and Alzheimer disease: The development of cerebrospinal fluid (CSF) and positron emission tomography (PET) markers of amyloid beta (Aβ) and tau (T) pathology has enabled clinico‐biological diagnosis of Alzheimer's disease (AD).1, 2, 3